Thompson Siegel & Walmsley LLC lowered its stake in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 6.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,886,173 shares of the medical instruments supplier's stock after selling 124,690 shares during the quarter. Baxter International makes up about 1.1% of Thompson Siegel & Walmsley LLC's holdings, making the stock its 26th biggest position. Thompson Siegel & Walmsley LLC owned 0.37% of Baxter International worth $71,618,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also modified their holdings of the stock. First PREMIER Bank purchased a new stake in shares of Baxter International in the 3rd quarter valued at about $25,000. Innealta Capital LLC acquired a new stake in shares of Baxter International in the second quarter valued at approximately $27,000. Fortitude Family Office LLC purchased a new position in shares of Baxter International during the third quarter worth approximately $38,000. LRI Investments LLC acquired a new position in shares of Baxter International in the 1st quarter valued at $39,000. Finally, Versant Capital Management Inc raised its position in Baxter International by 974.2% in the 2nd quarter. Versant Capital Management Inc now owns 1,332 shares of the medical instruments supplier's stock valued at $45,000 after purchasing an additional 1,208 shares during the last quarter. Hedge funds and other institutional investors own 90.19% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts have commented on the company. StockNews.com downgraded Baxter International from a "buy" rating to a "hold" rating in a research note on Monday, November 11th. JPMorgan Chase & Co. decreased their price target on Baxter International from $44.00 to $42.00 and set a "neutral" rating for the company in a report on Wednesday, August 7th. Citigroup boosted their price objective on shares of Baxter International from $38.00 to $40.00 and gave the company a "neutral" rating in a research note on Tuesday, October 1st. Stifel Nicolaus reduced their target price on shares of Baxter International from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Monday, November 11th. Finally, The Goldman Sachs Group boosted their price target on shares of Baxter International from $36.00 to $40.00 and gave the stock a "neutral" rating in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $40.91.
Check Out Our Latest Report on Baxter International
Baxter International Trading Up 1.5 %
BAX stock traded up $0.49 on Thursday, hitting $33.12. 2,297,824 shares of the company were exchanged, compared to its average volume of 4,104,977. The stock has a market capitalization of $16.91 billion, a price-to-earnings ratio of 165.46, a price-to-earnings-growth ratio of 12.91 and a beta of 0.60. The business's fifty day moving average is $36.46 and its two-hundred day moving average is $35.71. Baxter International Inc. has a twelve month low of $31.60 and a twelve month high of $44.01. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.43 and a quick ratio of 1.09.
Baxter International (NYSE:BAX - Get Free Report) last posted its earnings results on Friday, November 8th. The medical instruments supplier reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Baxter International had a net margin of 0.77% and a return on equity of 18.30%. The business had revenue of $3.85 billion for the quarter, compared to analyst estimates of $3.85 billion. During the same quarter in the previous year, the business posted $0.68 EPS. The business's quarterly revenue was up 3.8% on a year-over-year basis. As a group, research analysts forecast that Baxter International Inc. will post 1.98 earnings per share for the current year.
Baxter International Cuts Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, January 2nd. Shareholders of record on Friday, November 29th will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 2.05%. The ex-dividend date is Friday, November 29th. Baxter International's dividend payout ratio is presently 580.03%.
About Baxter International
(
Free Report)
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Recommended Stories
Before you consider Baxter International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.
While Baxter International currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.